Background: Erlotinib and pemetrexed are approved single agents for second-line treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic antitumor activity in NSCLC cell lines. We investigated the safety, pharmacokinetics and preliminary efficacy of combined erlotinib-pemetrexed in patients with refractory advanced NSCLC.
introduction
Lung cancer is the leading cause of cancer-related death in the United States, accounting for 29% of all cancer deaths [1] . The most common type of lung cancer is non-small-cell lung cancer (NSCLC), which accounts for 85%-90% of all lung cancer cases [2] . Limited treatment options are available for patients with NSCLC and response to first-line therapy is often short lived, with disease progression generally occurring 4-6 months after discontinuation of treatment [3] . The availability of improved long-term first-line options as well as effective second-line therapies is therefore of great importance.
Currently, three agents are approved for the second-line treatment of locally advanced or metastatic NSCLC-erlotinib, pemetrexed and docetaxel. Docetaxel (Taxotere Ò , Sanoti Aventis, Paris, France) was the first to be approved and became the initial standard of care for second-line NSCLC in suitable patients. Pemetrexed (Alimta Ò , Gli Lily & Co., Indianapolis, USA) is a multitargeted, antifolate, antineoplastic agent, which disrupts folate-dependent metabolic processes essential for cell replication [4] . Pemetrexed gained approval for second-line NSCLC treatment based on a phase III trial comparing pemetrexed with docetaxel [5] in which pemetrexed showed equivalent survival to docetaxel with improved tolerability.
More recently, the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib was shown to significantly improve survival, delay progression of symptoms and improve quality of life versus placebo in patients with advanced pretreated NSCLC in a randomized phase III study [6] . Erlotinib also has a favorable toxicity profile, with few grade 3/4 adverse events (AEs) and no hematologic toxicity.
The heterogeneity of NSCLC tumors provides a strong rationale for using combination therapy with targeted agents that have different mechanisms of action, offering scope for additive or possibly synergistic effects [7] . Furthermore, the favorable tolerability profiles of most targeted therapies may enable their combined use without unacceptable toxicity. This is in contrast to combination therapy using cytotoxic agents, where overlapping toxic effects mean that doses are more likely to be reduced, with corresponding reductions in efficacy [7] .
The combination of erlotinib and pemetrexed could potentially offer additional efficacy to that provided by either agent alone. In a preclinical study of erlotinib and pemetrexed in human NSCLC lines, a combination regimen or sequential treatment with pemetrexed followed by erlotinib led to synergistic anticancer effects in both erlotinib-sensitive and erlotinib-resistant cell lines. The effect was independent of EGFR or KRAS mutation status and was due to complementary cell cycle effects from both agents [8] .
To build on these promising preclinical data, the BP18193 (combination of Alimta and erlotinib) study was designed to investigate the combination of erlotinib and pemetrexed as second-line therapy in patients with advanced NSCLC.
materials and methods

study design
This nonrandomized, open-label, phase IB study evaluated erlotinib in combination with pemetrexed in patients with advanced NSCLC (stage IIIB/IV) whose disease had progressed on or after receiving standard first-line chemotherapy with a platinum-containing regimen or who were unsuitable to receive conventional first-line therapy. The primary objective of the study was to determine the maximum tolerated dose (MTD) of the combination, with MTD defined as the dose below that which led to unacceptable dose-limiting toxic effects (DLTs). Secondary objectives were to evaluate the safety profile of erlotinib-pemetrexed in the treatment of NSCLC, to determine the recommended combination dose of both drugs for future clinical trials and development, to explore the effects of each drug on the pharmacokinetics of the other agent, to evaluate the potential antitumor efficacy of erlotinib-pemetrexed in the treatment of NSCLC and to explore the correlation between antitumor activity and EGFR mutations and/or EGFR expression level.
Patients received erlotinib, given orally from day 3 of the first cycle, and pemetrexed, administered as a 10-min i.v. infusion once every 3 weeks, starting within 5 min of the erlotinib dose. Erlotinib dosing was commenced on day 3 to allow comparison of the pharmacokinetic profile of pemetrexed when administered alone versus administration in combination with erlotinib. There were five different dosing cohorts planned: cohort 1 (100 mg/day erlotinib and 500 mg/m 2 pemetrexed), cohort 2 (150 mg/day erlotinib and 500 mg/m 2 pemetrexed), cohort 3
(150 mg/day erlotinib and 600 mg/m 2 pemetrexed), cohort 4 (150 mg/day erlotinib and 700 mg/m 2 pemetrexed) and cohort 5 (150 mg/day erlotinib and 900 mg/m 2 pemetrexed). Six patients (three in cohort 1) were enrolled into each cohort in the first instance. Dose escalation was not permitted for individual patients. Patients received a vitamin B12 injection the week before their first pemetrexed administration and another injection of vitamin B12 every 9 weeks subsequently. Daily folic acid supplementation was initiated for 1 week before the first pemetrexed infusion and oral dexamethasone was given twice daily on the day before, the day of and the day following pemetrexed administration.
Combination treatment with erlotinib-pemetrexed was given until unacceptable toxicity, disease progression or death, up to a maximum of six cycles. After this time, erlotinib monotherapy could be continued until progression.
The study protocol was approved by an independent ethics committee and adhered to the principles outlined in the Guideline for Good Clinical Practice (January 1997) and Declaration of Helsinki (1996) . Written informed consent was obtained from all patients before commencement of the study.
patient selection
Patients were eligible for enrollment if they were aged ‡18 years with histologically documented, inoperable, locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, which had progressed on or following firstline chemotherapy with a platinum-containing regimen, or if they were considered unsuitable to receive conventional first-line therapy. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, measurable disease according to RECIST [9] , life expectancy of ‡12 weeks, ‡4 weeks elapsed since any surgery or radiotherapy, fully recovered from any radiotherapy-associated acute toxicity, hemoglobin ‡9 g/dl, platelet count >100 000/mm 2 , creatinine clearance ‡45 ml/min, serum bilirubin £1.5 · upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase <2.5 · ULN, alkaline phosphatase £2.5 · ULN, negative pregnancy test for all female patients of childbearing potential and use of an approved contraceptive for all patients of reproductive potential during and for 6 months after receiving study treatment.
Exclusion criteria included previous exposure to agents directed at the human epidermal receptor family or pemetrexed molecular targets, a history of hypersensitivity to erlotinib or pemetrexed and use of warfarin or coumarin derivatives. study outcomes safety. At screening and after each cycle of treatment, patients underwent physical examination and assessments of the following parameters: vital signs, ECOG performance status, hematology, biochemistry and urinalysis. All AEs and DLTs were reported throughout the study. AEs were graded according to National Cancer Institute-Common Toxicity Criteria v3.0.
[DLTs were defined as the following events: grade 3/4 non-hematologic toxicity (except for fever, chills and flu-like symptoms; alopecia; liver transaminase elevations; inadequately treated diarrhea; nausea and vomiting and tolerable rash); grade 4 neutropenia of >7 days duration; grade 3/4 febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding requiring platelet transfusions; grade 3/4 anemia; any treatment-related toxicity necessitating dose reduction or interruption of erlotinib during cycle 1; any treatment-related toxicity necessitating delayed pemetrexed administration in cycle 2; treatment-related death and any laboratory abnormality occurring during the first cycle that led to a subsequent dose reduction].
If more than one-third of patients in a cohort experienced DLTs, recruitment into the previous cohort would be expanded to 12 patients in order to confirm that dosing combination as the MTD.
pharmacokinetics. Blood samples (4 ml) were taken on days 1 and 22 (10 serial samples within 12 h of starting the pemetrexed infusion) and one sample in the morning on days 2, 3, 23 and 24 for the pharmacokinetic assessment of pemetrexed. For the pharmacokinetic assessment of erlotinib and its metabolite OSI-420, blood samples (3 ml) were obtained from patients in cohorts 1, 3, 4 and 5 on day 1 (one sample before the pemetrexed infusion), days 21 and 22 (nine samples each day within 12 h of erlotinib dosing) and day 23 (one sample before erlotinib dosing). Patients enrolled in cohort 2 had blood samples taken on day 1 (one sample before pemetrexed infusion), days 20 and 22 (nine samples each day within 12 h of original article Annals of Oncology erlotinib dose) and days 21, 23, 43, 64, 85 and 106 (one sample before erlotinib dosing). The following parameters were evaluated using model-independent methods: maximum plasma concentration (C max ), time to maximum plasma concentration (T max ), area under the plasma concentration versus time curve (AUC) over one dosing interval for erlotinib (AUC 0-s ), AUC from 0 to infinity for pemetrexed (AUC 0-N ), total plasma clearance for pemetrexed (CL), volume of distribution (V ss ) for pemetrexed and elimination half-life (t 1/2 ) for pemetrexed.
efficacy. Tumor assessments were carried out at the end of every two cycles. Best response to treatment of each patient was assessed according to RECIST.
biomarker analysis. At screening, a tumor block or tissue section was taken to determine EGFR expression level [assessed by immunohistochemistry (IHC)], EGFR mutation status and KRAS mutation status. For mutation analyses, microdissection was carried out on formalin-fixed paraffinembedded tissue sections. DNA lysates were then prepared from the microdissected tissue and amplifications of EGFR exons 18-21 and KRAS exons 2 and 3 were carried out using nested primers and PCR methodology. Samples were classified as 'mutated' if at least one classical mutation was detected and 'wild type' if no mutations were detected.
statistical analysis and sample size. The safety analysis included data from all patients who received at least one dose of erlotinib-pemetrexed. Sample size was dependent on the number of dose levels needed to reach the MTD. Up to five dose levels were expected, with three (cohort 1) or six patients per dose level, plus an additional six patients to confirm the MTD.
results patients A total of 20 patients from four sites were enrolled into the study (cohort 1, n = 3; cohort 2, n = 6; cohort 3, n = 6; cohort 4, n = 5). Recruitment was halted before any patients were enrolled into cohort 5 because of DLTs seen in cohort 4. At the same time, interim results from a phase III study of pemetrexed, comparing 500 and 900 mg/m 2 doses, indicated a low probability of a survival advantage with the higher dose and a somewhat greater incidence of toxicity [10] . It was, therefore, decided not to expand the MTD level (cohort 3) as 12 patients had already been treated between cohorts 2 and 3, all of whom received erlotinib and pemetrexed at or above the approved single-agent doses (150 mg/day and 500-600 mg/m 2 , respectively). The baseline characteristics of all patients are summarized in Table 1 .
safety The safety population comprised 20 patients who received at least one dose of erlotinib-pemetrexed. The median number of treatment cycles was 6 (range 3-6) for cohort 1, 3 (range 1-6) for cohort 2, 3 (range 1-5) for cohort 3 and 5 (range 1-6) for cohort 4.
All patients in the study experienced at least one AE, regardless of causality. Gastrointestinal and skin/subcutaneous tissue disorders were the most frequent categories of AEs, occurring in 90% and 85% of patients, respectively. The most common AEs were rash, diarrhea and fatigue (Table 2) . Four AEs led to withdrawal from the combination regimen of erlotinib and pemetrexed; two patients continued to receive erlotinib monotherapy and two other patients (one with cerebral stroke and one with fatigue, both in cohort 2) withdrew from treatment completely.
Significant laboratory abnormalities (i.e. those with an associated clinical condition, those which necessitated dose modification or interruption or those meeting the criteria for a serious AE) were reported and graded as AEs in all patients.
The majority of laboratory parameters tested showed less than or equal to two grade shifts from baseline value throughout the course of the study. There was no pattern of increasing shifts with increasing doses of study drug.
Serious AEs of any cause were reported in eight patients: confusional state (one patient, cohort 1), myocardial infarction (one patient, cohort 2), cerebrovascular accident (one patient, cohort 2), lower respiratory tract infection (one patient, cohort 3), pulmonary embolism (one patient, cohort 3), rash (one patient, cohort 4), pyrexia (two patients, cohort 4) and neutropenic sepsis (one patient, cohort 4). Only the serious AEs encountered in cohort 4 were considered to be treatment related.
A total of eight deaths occurred during the study, six of which were deemed a result of progressive disease (one patient, cohort 1; three patients, cohort 3 and two patients, cohort 4) and two of which were attributed to AEs (one patient, cohort 2 and one patient, cohort 3). The AEs that led to death were myocardial infarction and pulmonary embolism, neither of which was considered treatment related.
In total, 16 patients withdrew before receiving the planned six cycles of erlotinib-pemetrexed; the recorded reasons for withdrawal were AEs (n = 4), insufficient efficacy (n = 7), refusal of treatment (n = 2) and death (n = 3). Six of these patients continued to receive erlotinib monotherapy.
No DLTs were observed in cohorts 1-3, but three patients in cohort 4 reported at least one DLT: one patient had grade 3 skin rash with secondary infection (erlotinib dose was modified), one had grade 2 skin rash (requiring erlotinib dose modification in cycle 1) and one had grade 3 neutropenia, grade 3 anemia, grade 4 thrombocytopenia and grade 3 rash (erlotinib dose was modified).
pharmacokinetics Pharmacokinetic analyses of pemetrexed, erlotinib and the erlotinib metabolite OSI-420 were carried out to assess drug-drug interactions. No changes in the mean plasma concentration-time profiles of these agents were observed when taken concurrently (Figure 1) .
The pharmacokinetic parameters (Table 3) were comparable between days 1 and 22 for pemetrexed (i.e. between the start of cycle 1 with pemetrexed alone and the start of cycle 2 where both drugs were coadministered) and were also comparable for erlotinib between days 20 and 22 (i.e. between a day when only erlotinib was administered and one in which both drugs were administered). Data are presented for cohort 2; however, similar results were observed in all cohorts. efficacy A tumor response assessment was carried out for 18 patients (90%) enrolled in the study. Two patients withdrew from the trial before any post-screening tumor assessment could be carried out (one patient from cohort 2 withdrew due to an AE and one patient from cohort 3 died). The best response achieved from start of treatment to time of progression is summarized in Table 4 ; the overall disease control rate was 55%.
biomarker analysis
Of the 20 patients enrolled in this study, EGFR mutational status was determined for 7 patients [one patient had an EGFR mutation (exon 19 deletion) and the others had wild-type AUC is AUC 0-N for pemetrexed and AUC 0-s for erlotinib. T max , time to maximum plasma concentration; C max , maximum plasma concentration; AUC, area under the curve; t 1/2 , half-life; V ss , volume of distribution at steady state; CL, clearance; SD, standard deviation; -, not available.
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EGFR], EGFR expression was determined for 12 patients (11 were EGFR IHC positive and 1 was EGFR IHC negative) and KRAS mutation status was obtained for 9 patients (2 had KRAS mutations and 7 had wild-type KRAS). Suitable samples could not be obtained for the remaining patients in the study; therefore, their mutational status could not be determined.
Of the 10 EGFR IHC-positive patients with response data available, 1 had a partial response, 5 had stable disease and 4 had progressive disease. The patient identified as EGFR IHC negative had stable disease with the erlotinib-pemetrexed combination. One patient who had a confirmed EGFR mutation also had stable disease with the study regimen, as did four of the six patients who had confirmed wild-type EGFR (the remaining two patients had progressive disease). In the two patients with KRAS mutations, one had stable disease up to week 24 and the other had progressive disease.
Based on these available data, it is not possible to reach any definitive conclusion on the potential correlation of EGFR expression, EGFR mutational status or KRAS mutational status and clinical outcome, due to the small patient numbers involved and the different doses that each patient received.
discussion
Treatment with erlotinib-pemetrexed was generally well tolerated, and reported AEs were similar to those observed in previous studies of each agent alone [5, 6] , with little additive toxicity. The most common AEs were gastrointestinal and skin/ subcutaneous disorders, which are consistent with phase III studies of erlotinib and pemetrexed monotherapy [5, 6] . Although these AEs occurred in a high number of patients (90% and 85%, respectively), the majority were grade 1 or 2 in severity and none led to treatment withdrawal. Overall, administering erlotinib and pemetrexed concurrently led to a favorable toxicity profile.
The primary objective of the study was to determine the MTD of erlotinib-pemetrexed in NSCLC. However, following the decision not to continue investigations of pemetrexed doses >500 mg/m 2 , the MTD was not definitively confirmed as originally detailed in the protocol. Nevertheless, the fact that no DLTs were observed in the six patients in cohort 3 who received a median of three cycles indicates strongly that erlotinib 150 mg/day and pemetrexed 600 mg/m 2 is an acceptable dosing regimen. This dose of pemetrexed has not been compared with the approved dose of 500 mg/m 2 . However, the 900 mg/m 2 dose of pemetrexed is not superior to 500 mg/m 2 based on the results seen in the study by Cullen et al. [10] , so it is unlikely that pemetrexed 600 mg/m 2 is substantially more efficacious than the 500 mg/m 2 dose in combinations with erlotinib. This conclusion is supported by the lack of any pharmacokinetic interactions between erlotinib and pemetrexed when administered concurrently. This result was not unexpected since the two drugs have different methods of elimination. After oral administration, erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2 and CYP1A1, then excreted in the feces [11] . In contrast, pemetrexed is administered by infusion, not metabolized to any appreciable extent and primarily eliminated in the urine [12] . Oral dexamethasone is given twice daily on the day before, the day of and the day following the pemetrexed infusion. Although erlotinib is a substrate of CYP3A4 and is known to be sensitive against inducers, short-term administration over 3 days of 4 mg dexamethasone, a known inducer, did not appear to decrease erlotinib concentrations.
When cohorts 2 and 3, in which patients received both drugs at or above the approved single-agent doses, are considered together, there were no DLTs in 12 patients. This clearly indicates that erlotinib and pemetrexed can safely be administered together at doses of 150 mg/day and 500 mg/m 2 , respectively, confirming that the regimen is suitable for further evaluation.
The small sample size in the current study precludes any definitive conclusions regarding efficacy or potential correlations between EGFR expression or EGFR/KRAS mutational status and clinical outcome. Preclinical synergy was independent of EGFR or KRAS mutation status [8] . Phase II and III studies would be required to clinically address this question and to determine whether there is additive or synergistic antitumor effect with erlotinib-pemetrexed. Preclinical studies have indicated a synergistic cytotoxic effect in human NSCLC lines [8, 13] and this appears to be mediated by several mechanisms. In particular, reduced phosphorylation of EGFR and Akt was observed with the combination therapy, leading to enhanced induction of apoptosis. Thymidylate synthase activity was also much reduced when both agents were used, compared with either agent alone [13] .
Erlotinib has previously been studied in combination with chemotherapy in first-line NSCLC in two large phase III studies [14, 15] . The combination of erlotinib with platinum-based chemotherapy regimens did not improve survival or other outcomes. However, in another study in advanced pancreatic cancer, erlotinib plus gemcitabine significantly improved overall survival, 1-year survival and progression-free survival [16] , compared with gemcitabine alone. Such contrasting data indicate that the synergism between erlotinib and chemotherapy agents may be either disease or regimen specific.
The previous lack of significant additional clinical activity when erlotinib was administered concurrently with chemotherapy for NSCLC may have been due to antagonism between the cytostatic effects of erlotinib (which arrests the cell cycle in G 1 phase) and the cytotoxic effect of chemotherapy. However, when schedule-dependent dosing was investigated in Table 4 . Best response to erlotinib-pemetrexed combination treatment original article Annals of Oncology preclinical studies, pemetrexed followed by erlotinib or concurrent administration both provided synergistic efficacy, but erlotinib followed by pemetrexed did not [8] . It is, therefore, possible that more positive outcomes could be obtained with erlotinib plus chemotherapy by optimizing the dosing schedule or perhaps by selecting patients whose tumors have specific molecular characteristics. However, although higher response rates to erlotinib have been reported in patients with EGFR-activating mutations [17] , data from the phase III study of erlotinib monotherapy showed that the survival benefits of erlotinib were not restricted to those patients with EGFR-activating mutations [6] , and correlative studies indicated that the presence of an EGFR mutation may increase responsiveness to erlotinib but is not an independent indicator of survival benefit [18] .
The prospect of combining erlotinib with another targeted therapy is also appealing, as it may allow multiple pathways to be specifically targeted with manageable toxicity. However, there are complicating factors in combining two targeted agents with complex mechanisms of action, and there is still a clear role for chemotherapy in advanced cancer where a broad-spectrum approach may be required. Further studies are already underway to test erlotinib in combination with other targeted therapies, either sequentially or concurrently.
Recent studies investigating the use of erlotinib and pemetrexed as maintenance therapy following nonprogression with first-line chemotherapy in NSCLC have shown promising efficacy for both agents [19] [20] [21] . If future studies of the erlotinib-pemetrexed combination in second-line NSCLC show improved activity over either agent alone, then further investigation of this combined regimen in the maintenance setting may be warranted.
In conclusion, the present study indicates that erlotinib (150 mg/day) combined with pemetrexed (500 mg/m 2 ) is a feasible, well-tolerated combination therapy that may add to the current therapeutic armamentarium for patients with advanced NSCLC. Further investigation of this combination is warranted to investigate any additional or synergistic efficacy benefits from the combination regimen. 
